Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000533866 | SCV000636969 | likely benign | Dilated cardiomyopathy 1AA; Primary familial hypertrophic cardiomyopathy | 2024-11-18 | criteria provided, single submitter | clinical testing | |
CHEO Genetics Diagnostic Laboratory, |
RCV000769745 | SCV000901167 | uncertain significance | Cardiomyopathy | 2015-09-25 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV002483404 | SCV002775188 | uncertain significance | Dilated cardiomyopathy 1AA; Myopathy, congenital, with structured cores and z-line abnormalities; Myopathy, distal, 6, adult-onset, autosomal dominant | 2021-07-06 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV003302813 | SCV003997195 | uncertain significance | Cardiovascular phenotype | 2023-06-05 | criteria provided, single submitter | clinical testing | The p.R140H variant (also known as c.419G>A), located in coding exon 4 of the ACTN2 gene, results from a G to A substitution at nucleotide position 419. The arginine at codon 140 is replaced by histidine, an amino acid with highly similar properties. This amino acid position is highly conserved in available vertebrate species. In addition, the in silico prediction for this alteration is inconclusive. Since supporting evidence is limited at this time, the clinical significance of this alteration remains unclear. |